Type 1 Diabetes Vaccine: Does Diamyd Have a Winning Formula?
XTalks
SEPTEMBER 15, 2020
A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. Specifically, the vaccine contains human recombinant glutamate decarboxylase 65 (GAD65) protein conjugated to aluminum hydroxide (GAD-alum).
103 
Let's personalize your content